Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | PAK4 | O96013 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.39 |
| ▸ | CLK2 | P49760 | 3/20 | 0.39 |
| ▸ | CDK7 | P50613 | 3/20 | 0.39 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | PRKX | P51817 | 3/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | MELK | Q14680 | 3/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.39 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.39 |
| ▸ | CDK8 | P49336 | 2/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.39 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436681 | 0.95 | CDC7 (0.40) | CDC7DAPK3ROCK2PAK4CDK2 | |
| SCHEMBL20436683 | 0.94 | CDC7 (0.39) | CDC7DAPK3ROCK2PAK4CDK2 | |
| SCHEMBL20416698 | 0.93 | CDC7 (0.38) | CDC7DAPK3ROCK2PAK4CDK2 | |
| SCHEMBL30401921 | 0.93 | CDC7 (0.38) | CDC7DAPK3ROCK2PAK4CDK2 | |
| SCHEMBL20436691 | 0.93 | CDC7 (0.39) | CDC7DAPK3ROCK2PAK4CDK2 | |
| SCHEMBL30400816 | 0.93 | CDC7 (0.39) | CDC7DAPK3ROCK2PAK4CDK2 | |
| SCHEMBL20400630 | 0.93 | CDC7 (0.39) | CDC7DAPK3ROCK2PAK4CDK2 | |
| SCHEMBL20436684 | 0.93 | CDC7 (0.39) | CDC7DAPK3ROCK2PAK4CDK2 | |
| SCHEMBL20436688 | 0.92 | CPT2 (0.39) | CDC7DAPK3ROCK2PAK4CDK2 | |
| SCHEMBL30401185 | 0.90 | CDC7 (0.38) | CDC7DAPK3ROCK2PAK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | CDC7 780/4885DAPK3 1495/4885ROCK2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.